Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

Recent & Breaking News (NDAQ:LEXX)

Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market

Accesswire June 3, 2022

Lexaria Grants License to Valcon Medical for the European Market

TheNewsWire June 2, 2022

Lexaria Announces 2022 Annual Meeting Results

Accesswire June 1, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

GlobeNewswire May 26, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

GlobeNewswire May 25, 2022

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

Accesswire April 21, 2022

Lexaria Commences Multi-Week Human Clinical Hypertension Study

Accesswire April 19, 2022

Lexarias Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

TheNewsWire April 14, 2022

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

Accesswire April 14, 2022

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

TheNewsWire April 12, 2022

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

TheNewsWire April 11, 2022

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

TheNewsWire March 15, 2022

Lexaria Granted Important New Oral Nicotine Patent

TheNewsWire March 8, 2022

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

TheNewsWire February 2, 2022

Lexaria Provides Annual Letter From the CEO

TheNewsWire January 27, 2022

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

TheNewsWire January 18, 2022

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

TheNewsWire December 29, 2021

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

TheNewsWire December 16, 2021

Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

TheNewsWire December 14, 2021

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Accesswire December 8, 2021